FIELD: pharmaceutics.
SUBSTANCE: compounds of formula (I) R1 is halogen atom; (C1-C6) alkyl, optionally substituted with one or more halogen atoms; (C1-C6) alkoxy group, optionally substituted with one or more halogen atoms, or -(CH2)nNHRa, where Ra represents hydrogen atom; -C(O)-(CH2)n-phenyl or -C(O)-(CH2)n-pyridyl, where phenyl is optionally substituted with one or more substitutes of halogen atom; -SCF3; (C1-C6)alkyl, optionally substituted with one or more halogen atoms, or (C1-C6)alkoxy group, optionally substituted with one or more halogen atoms; -C(O)-(C1-C8)alkyl, where alkyl is optionally substituted with one or more halogen atoms; -C(O)-(CH2)n-(C3-C10-cycloalkyl); -C(O)-(CH2)n-NRbRc, where Rb and Rc are hydrogen atoms independently of each other; (C1-C6)alkyl; or phenyl, optionally substituted with one or more substitutes of halogen atom or (C1-C6)alkyl; -C(O)-(CH2)n-O-(C1-C6)alkyl; or -C(O)-(CH2)n-O-(CH2)n-phenyl; R2 is hydrogen atom; OH; phenyl or (C1-C6) alkyl, optionally substituted with one or more halogen atoms; R3 is hydrogen atom; or (C1-C6) alkyl; and n takes values 0, 1 or 2.
EFFECT: method is disclosed of treating or controlling diseases or disorders, such as cancer involving administering 5-substituted quinazoline compound of formula (I) or its pharmaceutically acceptable salt, solvate or stereoisomer.
32 cl, 59 ex
